A randomized multicenter phase II trial to evaluate the safety and efficacy of vaccination with folate receptor alpha (FRα) peptides admixed with GM-CSF as an adjuvant versus GM-CSF alone in patients with platinum-sensitive ovarian cancer (EOC).

Authors

Roisin Eilish O'Cearbhaill

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

Roisin Eilish O'Cearbhaill , Jason A. Konner , Matthew Stephen Block , James Potts , Gerald Garrett , Richard Kenney , Robert Michael Wenham

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01.

First Author: Snehal Patel

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Final five-year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the use of HER2/neu peptide GP2 + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer.

First Author: Snehal Patel

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study.

First Author: Eleftheria A Anastasopoulou

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone.

First Author: A. K. Sears